An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's).

Abstract

OBJECTIVES To determine the safety and efficacy of abatacept in non-severe relapsing granulomatosis with polyangiitis (Wegener's)(GPA). METHODS An open-label trial of intravenous abatacept was conducted in 20 patients with non-severe relapsing GPA. Prednisone up to 30 mg daily was permitted within the first 2 months, and patients on methotrexate… (More)
DOI: 10.1136/annrheumdis-2013-204164

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.